Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort.

Matthew K SmithYin ChanAleksi E SuoAbdel Aziz ShaheenStephen E ConglyPuneeta TandonRahima A BhanjiMalcolm M WellsTina ChengChristopher Ma

Published in: Journal of the Canadian Association of Gastroenterology (2021)

Approximately half of the patients treated with combination ipilimumab and nivolumab developed IMH in this cohort. However, most patients experienced uncomplicated IMH resolution.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
clinical trial
peritoneal dialysis
prognostic factors
single molecule
patient reported outcomes
patient reported
combination therapy
double blind
smoking cessation